Uridine Triacetate - National Cancer Institute

Uridine Triacetate - National Cancer Institute







Uridine Triacetate for Overdose and Toxicity

We've added a new drug summary for uridine triacetate, which is used to treat overdose of certain drugs used to treat cancer or to treat cardiac and nervous system toxicity caused by these drugs.

Uridine Triacetate

• 
• 
• 
• 
• 
• 
• 

listen (YOOR-ih-deen try-A-seh-tayt)

This page contains brief information about uridine triacetate and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.

US Brand Name(s)

Vistogard

FDA Approved

Yes

FDA Approval for Uridine Triacetate

Use in Cancer

Uridine triacetate is approved to be used in the emergency treatment of:

• Overdoses of fluorouracil or capecitabine.
• Cardiac (heart) or central nervous system toxicity or other serious side effects within 4 days of ending treatment with fluorouracil or capecitabine.

Uridine triacetate is also being studied in the treatment of other conditions.

More About Uridine Triacetate

Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.

Clinical Trials Accepting Patients

Find Clinical Trials for Uridine Triacetate - Check for trials from NCI's list of cancer clinical trials now accepting patients.

Important: The drug information on this page is meant to be educational. It is not a substitute for medical advice. The information may not cover all possible uses, actions, interactions, or side effects of this drug, or precautions to be taken while using it. Please see your health care professional for more information about your specific medical condition and the use of this drug.